ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Mupirocin: Drug information

Mupirocin: Drug information
2024© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Mupirocin: Patient drug information" and "Mupirocin: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Centany AT [DSC];
  • Centany [DSC]
Pharmacologic Category
  • Antibiotic, Topical
Dosing: Adult
Peritoneal dialysis catheter exit-site or tunnel infection, prophylaxis

Peritoneal dialysis catheter exit-site or tunnel infection, prophylaxis (off-label use):

Topical: Cream: Apply once daily to catheter exit site to prevent infection (Ref). Note: Cream is preferred to ointment, which may damage some catheters (Ref).

Staphylococcus aureus decolonization

Staphylococcus aureus (including methicillin-resistant) decolonization:

Note: For select patients who have recurrent S. aureus infection or warrant preoperative decolonization (Ref).

Intranasal (off-label use):

Note: Intranasal mupirocin ointment is no longer available in the United States.

Ointment: Apply into each nostril (an amount sufficient to cover the top of a cotton swab [~500 mg]) twice daily for 5 to 10 days in combination with a skin antiseptic (eg, chlorhexidine body wash); dose extrapolated from intranasal formulation (Ref). Note: Some experts suggest decolonization at discharge for hospitalized patients with methicillin-resistant S. aureus colonization or infection; in such cases, a 5-day course in combination with chlorhexidine body wash and mouthwash is repeated twice monthly for 6 months (Ref).

Superficial skin infection

Superficial skin infection:

Folliculitis (off-label use): Topical: Ointment: Apply to affected area 3 times daily, typically for 7 days depending on severity and clinical response (Ref).

Impetigo (limited number of lesions): Topical: Ointment: Apply to affected area 2 to 3 times daily for 5 days (Ref).

Nasal vestibulitis (off-label use): Intranasal: Ointment: Apply to affected nostril(s) twice daily for 5 days (Ref).

Secondary skin infection (localized infection of wounds, burns, dermatitis, or other lesions): Topical: Cream, Ointment: Apply to affected area 2 to 3 times daily, typically for 7 to 14 days depending on severity and clinical response; if no response after 3 to 5 days, re-evaluate treatment (Ref).

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Mupirocin: Pediatric drug information")

Staphylococcus aureus decolonization

Staphylococcus aureus (methicillin-resistant or -susceptible) decolonization:

Nasal site: Note: Intranasal mupirocin ointment is no longer available in the United States; some dosing extrapolated from intranasal formulation.

Infants, Children, and Adolescents: Ointment: Limited data available: Topical: Apply a small amount (eg, approximately pea-sized) to both anterior nares twice daily for 5 to 10 days; often used concomitantly with a skin decontamination regimen (Ref).

Superficial skin infection

Superficial skin infection:

Impetigo with limited lesions: Limited data available in ages <2 months: Infants, Children, and Adolescents: Ointment: Topical: Apply to affected area 2 to 3 times daily for 5 days; patients not showing clinical response after 3 to 5 days should be reevaluated (Ref).

Secondary skin infection with minor skin lesions: Cream (limited data in ages <3 months), Ointment (limited data available): Infants, Children, and Adolescents: Cream, Ointment: Topical: Apply to affected area 2 to 3 times daily for 7 to 10 days; patients not showing clinical response after 3 to 5 days should be reevaluated (Ref).

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

1% to 10%:

Dermatologic: Pruritus (≤1%), skin rash (≤1%), stinging of the skin (≤2%)

Gastrointestinal: Nausea (≤1%)

Local: Local pain (≤2%), localized burning (≤2%)

Nervous system: Headache (2%)

<1%:

Dermatologic: Cellulitis, dermatitis (including contract dermatitis), erythema of skin, xeroderma

Gastrointestinal: Abdominal pain, aphthous stomatitis

Infection: Secondary infection (wound)

Local: Local swelling, localized tenderness

Nervous system: Dizziness

Postmarketing: Hypersensitivity: Hypersensitivity reaction (including anaphylaxis and angioedema)

Contraindications

Hypersensitivity to mupirocin or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity: May be associated with systemic allergic reactions, including anaphylaxis, urticaria, angioedema, and generalized rash. If a systemic reaction occurs, discontinue use.

• Irritation: If sensitization or local irritation occurs, discontinue use.

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.

• Polyethylene glycol: Potentially toxic amounts of polyethylene glycol contained in some topical products may be absorbed percutaneously in patients with extensive burns or open wounds. Do not use polyethylene glycol-based ointments in conditions where absorption of large quantities of polyethylene glycol is possible, especially in the presence of moderate or severe renal impairment.

Other warnings/precautions:

• Appropriate use: For external use only. May cover treated areas with gauze dressing. Ointment should not be used with IV cannulae or at central IV sites because of the potential to promote fungal infections and antimicrobial resistance. Cream and ointment are not indicated for ophthalmic or nasal use or use on mucosal surfaces; in case of accidental contact in or near eyes, rinse well with water. If ointment applied intranasally (off-label use), may cause severe burning and tearing in eyes (resolves within days to weeks after discontinuation).

Warnings: Additional Pediatric Considerations

Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Cream, External, as calcium [strength expressed as base]:

Generic: 2% (15 g, 30 g)

Kit, External:

Centany AT: 2% [DSC] [contains propylene glycol monostearate]

Ointment, External:

Centany: 2% (30 g [DSC]) [contains propylene glycol monostearate]

Generic: 2% (1 g, 15 g, 22 g)

Generic Equivalent Available: US

May be product dependent

Pricing: US

Cream (Mupirocin Calcium External)

2% (per gram): $1.81 - $16.37

Ointment (Mupirocin External)

2% (per gram): $0.51 - $3.89

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Adult

Intranasal (ointment) (off-label route): After application into nostrils, press sides of nose together and gently massage to spread ointment throughout the insides of the nostrils for ~1 minute. Do not apply concurrently with any other intranasal products. Wash hands before and after application. In case of accidental contact in or near eyes, rinse well with water (Ref).

Topical (cream, ointment): For external use only; not for use in eyes or on mucous membranes (components may be absorbed systemically and cause drying and irritation). Apply small amount to affected area using gauze pad or cotton swab; area may be covered with a gauze dressing if desired. In case of accidental contact in or near eyes, rinse well with water. Wash hands before and after application.

Administration: Pediatric

Topical: Wash hands before and after application.

Ointment:

Nasal site: Apply to anterior nares (enough to cover nasal mucosa); press sides of the nose together and gently massage for ~1 minute after application to spread ointment throughout the inside of the nostrils. Not for use in eyes. In case of accidental contact in or near eyes, rinse well with water. Do not apply concurrently with any other intranasal products (Ref).

Skin site (eg, umbilical site, impetigo, secondary skin infection): For external use only; not for use in eyes or on mucous membranes (components may be absorbed systemically and cause drying and irritation). Apply a small amount to affected area using cotton swab or gauze pad; may cover area with gauze dressing if desired. In case of accidental contact in or near eyes, rinse well with water. Do not use concurrently with any other lotions, creams, or ointments.

Cream: Skin site (eg, umbilical site, impetigo, secondary skin infection): For external use only; not formulated for use on mucosal surfaces; do not apply into the eye or use intranasally (components may be absorbed systemically and cause drying and irritation). Apply a small amount to affected area using cotton swab or gauze pad; may cover area with gauze dressing if desired. In case of accidental contact in or near eyes, rinse well with water. Do not use concurrently with any other lotions, creams, or ointments.

Use: Labeled Indications

Impetigo: Treatment of impetigo due to Staphylococcus aureus and Streptococcus pyogenes (topical ointment).

Secondary skin infection: Treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm2 in area) due to susceptible isolates of S. aureus and S. pyogenes (topical cream).

Use: Off-Label: Adult

Folliculitis; Nasal vestibulitis; Peritoneal dialysis catheter exit-site or tunnel infection, prophylaxis; Staphylococcus aureus (including methicillin-resistant) decolonization

Medication Safety Issues
Sound-alike/look-alike issues:

Bactroban may be confused with bacitracin, baclofen, Bactrim

Metabolism/Transport Effects

None known.

Drug Interactions

There are no known significant interactions.

Pregnancy Considerations

Systemic absorption following topical application is minimal.

Breastfeeding Considerations

It is not known if mupirocin is present in breast milk. Systemic absorption following topical application is minimal and significant exposure to a breastfeeding infant is not expected.

The American Academy of Breastfeeding Medicine recommends topical mupirocin for superficial skin infection associated with skin trauma in breastfeeding patients (ABM [Berens 2016]). Mupirocin is applied after breastfeeding in conjunction with cleaning the affected area. Topical treatment is not effective for systemic infection that may lead to mastitis (Livingstone 1999).

Per the manufacturer, if treatment to the breast and/or nipple is needed, the area should be thoroughly washed prior to breastfeeding to limit potential exposure of mupirocin to the infant; the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Mechanism of Action

Binds to bacterial isoleucyl transfer-RNA synthetase resulting in the inhibition of protein synthesis

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Penetrates outer layers of skin; systemic absorption minimal through intact skin.

Protein binding: >97%.

Metabolism: Rapidly metabolized to monic acid (inactive) following IV or oral administration.

Half-life: IV: 20 to 40 minutes.

Excretion: Urine (as monic acid [inactive]).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Avoban | Bactroban | Mupin | Mupirocin | Pirom | Supirocin;
  • (AR) Argentina: Bactroban | Mupax | Mupiderm | Mupirox | Paldar | Quemicetina nasal nf | Vidox;
  • (AT) Austria: Bactroban | Infectopyoderm;
  • (AU) Australia: Apo-mupirocin | Bactroban | Medicianz mupirocin | Medsurge mupirocin nasal;
  • (BD) Bangladesh: Bacron | Bactoderm | Bactriben | Bactroban | Bactropen | Dermasoft | Dermocin | Dermupin | Mupi | Mupibac | Mupiderm | Mupiron | Muroderm | Muron | Piroban | Sinaban | Skinobac | Systop | Trego;
  • (BE) Belgium: Bactroban;
  • (BG) Bulgaria: Bactroban | Mupirodermal | Mupironasal;
  • (BR) Brazil: Bacrocin | Bactocin | Bactroban | Bactroneo | Dermoban | Mupirocina | Supirocin;
  • (CH) Switzerland: Bactroban;
  • (CI) Côte d'Ivoire: Purocine;
  • (CL) Chile: Bactroban | Bantix | Mupax | Mupax nasal | Mupicil | Paldar | Ultrabiotic | Underan;
  • (CN) China: Bactroban | Bai duo bang;
  • (CO) Colombia: Bactroban | Mupicare | Mupiral | Presiderm;
  • (CZ) Czech Republic: Bactroban;
  • (DE) Germany: Bactroban | Infectopyoderm | Mupirocin infectopharm | Turixin;
  • (DO) Dominican Republic: Bactriderm | Bactroban | Mupifen | Mupiral | Presiderm | Supirocin;
  • (EC) Ecuador: Bagobiotic | Mupax | Mupiral | Mupirocina | Paldar | Presiderm | Seladerm | Underan;
  • (EE) Estonia: Bactroban | Humobact 15;
  • (EG) Egypt: Bactroban | Bactrocin | Bactroform | Mupirax | Probactcin;
  • (ES) Spain: Bactroban | Mupirocina dermogen | Mupirocina galenic | Mupirocina isdin | Plasimine;
  • (ET) Ethiopia: Bactroban | Baktocid | Solu m;
  • (FI) Finland: Bactroban;
  • (FR) France: Bactroban | Mupiderm | Mupirocin sandoz | Mupirocine arrow | Mupirocine biogaran | Mupirocine eg | Mupirocine mylan | Mupirocine pierre fabre;
  • (GB) United Kingdom: Bactroban;
  • (GR) Greece: Bactroban | Bactrocine | Hevronaz | Micoban;
  • (HK) Hong Kong: Bacterocin | Bactrian | Bactroban | Mupider | Muprin | Muropa | Supirocin;
  • (HR) Croatia: Betrion mast | Mirobact | Mupiron;
  • (HU) Hungary: Bactroban | Bactrocine | Mupirocin infectopharm;
  • (ID) Indonesia: Bactoderm | Bactroban | Mertus | Pibaksin;
  • (IE) Ireland: Bactroban;
  • (IL) Israel: Bactoderm | Bactroban;
  • (IN) India: B bact | B fence | Bactibade | Bacticin | Bactroban | Baktocid | Dataron | Dermocin | Epicin | Hmc bact | Impycid | Lifecin | M sys | Mcin | Microcin | Mocin | Mopry | Mpcin | Mpee | Mu | Mucidal | Mufect | Mupact | Mupibac | Mupibact | Mupiban | Mupic | Mupicet | Mupicost | Mupidac | Mupifen | Mupimesh | Mupin | Mupinase | Mupinity | Mupinova | Mupirax | Mupired | Mupiroc | Mupirol | Mupiron | Mupisoft | Mupitome | Mupitret | Mupivolt | Mupiways | Muply | Mupricon | Mupritis | Muprozyg | Musaf | Pirocin | Rociderm | Sterbact | Supirocin | T-bact | Topibact;
  • (IT) Italy: Bactroban | Bactroban nasale | Mupiskin | Pserocina | Pserocina nasale;
  • (JO) Jordan: Avoban | Bactroban | Bactroderm;
  • (JP) Japan: Bactroban;
  • (KE) Kenya: B bact | Bactopic | Bactroban | Bactrobel | Mupisoft | Supirocin | Zupricin;
  • (KR) Korea, Republic of: Antista | Bacterocin | Bactran | Bactrian | Bactroban | Bactrocin | Bearoban | Bentasone | Esroban | M picin | Mupiroban | Murocin | Murosin | Sy mupirocin;
  • (KW) Kuwait: Bactroban;
  • (LB) Lebanon: Avoban | Bactroban;
  • (LT) Lithuania: Bactroban | Infectopyoderm | Turixin;
  • (LU) Luxembourg: Bactroban;
  • (LV) Latvia: Bactroban | Turixin;
  • (MA) Morocco: Bactroban;
  • (MX) Mexico: Bacskin | Bactroban | Berniver | Dermucor S | Mupirocina | Sinpebac;
  • (MY) Malaysia: Bactopic | Bactricin | Bactroban | Mupicin | Mupirocin | Muposten | Murozin | Pirobact | Supirocin;
  • (NG) Nigeria: Bactroban | Supirocin;
  • (NL) Netherlands: Bactroban | Mupirocine | Mupirocine PCH;
  • (NO) Norway: Bactroban | Bactroban nasal nordic prime | Infectopyoderm | Mupirocine infectopharm | Turixin;
  • (NZ) New Zealand: Bactroban | Medicianz mupirocin;
  • (PE) Peru: Bagobiotic | Mupibiot | Mupiderm | Mupirocina | Mupirotrim | Mupirox | Murocyn | Setilax | Spectroderm | Supirocin | Underan;
  • (PH) Philippines: Bactifree | Bactreat | Bactriderm | Bactrigon | Bactroban | Bactrocin | Dermpibac | Diapurocin | Flovicide | Foskina | Microscot | Mirocid | Mupi | Mupiban | Mupicin | Mupiderm | Mupizee | S troban | Supiroban;
  • (PK) Pakistan: Antibac skin | Austaban | Bactoderm | Bactroban | Impecin | Imperocin | Irocin | Lintoban | Mupex | Mupiderm | Mupir | Mupira | Mupiron | Mupream | Muricin | Murocen | Mutrum | Trego | Tryderm | Upirox | Verocin;
  • (PL) Poland: Bactroban | Mupina | Mupirox | Soltopin | Taconal;
  • (PR) Puerto Rico: Bactroban | Centany | Mupirocin;
  • (PT) Portugal: Bactroban | Mupirocina | Mupirocina isdin;
  • (PY) Paraguay: Bactroban | Bantix | Mupax | Mupax nasal | Mupirox | Underan;
  • (QA) Qatar: Avoban | Bacoderm | Bactroban Cream | Bactroban Nasal | Bactroban Ointment | Dextrocin | Supirocin Ointment;
  • (RO) Romania: Bactroban;
  • (RU) Russian Federation: Bactroban | Bonderm | Supirocin;
  • (SA) Saudi Arabia: Avoban | Bactroban | Supirocin;
  • (SE) Sweden: Bactroban;
  • (SG) Singapore: Bactroban | Mupirax | Muprin | Supirocin;
  • (SI) Slovenia: Bactroban | Betrion;
  • (SK) Slovakia: Bactroban;
  • (TH) Thailand: Acdhon | Bacidal | Bacobye | Bactafect | Bactex | Bacticin | Bactokil | Bactroban | Banbact | Macroban | Mulacin | Muporin | Muprin | Piroban | Supirocin;
  • (TN) Tunisia: Bactroban;
  • (TR) Turkey: Bacmirpi | Bacoderm | Bactroban | Balaban | Dextrocin | Mupiderm | Mupiron | Mupobel;
  • (TW) Taiwan: Bactermin | Bactroban;
  • (UA) Ukraine: Bactialis | Bactopic | Bactroban | Bonderm;
  • (UG) Uganda: Bactroban | Supirocin;
  • (UY) Uruguay: Bactroban | Mupax | Mupilav | Mupirin | Mupirin nasal | Vidox;
  • (VE) Venezuela, Bolivarian Republic of: Bactroban | Dalcitrin | Multiderm | Muproban | Presiderm;
  • (VN) Viet Nam: Atimupicin | Phitrenone | Tropeal;
  • (ZA) South Africa: Bactroban | Banogon | Dermoban | Nuban | Supiroban;
  • (ZM) Zambia: Bactroban | Monsin | Supirocin | Topibact;
  • (ZW) Zimbabwe: Bactroban | Supirocin
  1. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  2. Arora HS, Khan H, Ailumerab H, et al. A tale of two intensive care units (ICUs): baseline Staphylococcus aureus colonization and mupirocin susceptibility in neonatal and pediatric patients requiring intensive care. Infect Control Hosp Epidemiol. 2023;44(3):447-452. doi:10.1017/ice.2022.96 [PubMed 35450544]
  3. Bactroban (mupirocin) nasal ointment [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2017.
  4. Berens P, Eglash A, Malloy M, Steube AM. ABM clinical protocol #26: persistent pain with breastfeeding. Breastfeed Med. 2016;11(2):46-53. [PubMed 26881962]
  5. Bertin ML, Vinski J, Schmitt S, et al, "Outbreak of Methicillin-Resistant Staphylococcus aureus Colonization and Infection in a Neonatal Intensive Care Unit Epidemiologically Linked to a Healthcare Worker With Chronic Otitis," Infect Control Hosp Epidemiol, 2006, 27(6):581-5. [PubMed 16755477]
  6. Bhattacharyya N. Nasal obstruction: Diagnosis and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed April 17, 2023.
  7. Bode LG, Kluytmans JA, Wertheim HF, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med. 2010;362(1):9-17. doi:10.1056/NEJMoa0808939 [PubMed 20054045]
  8. Bork K, Brauers J, Kresken M. Efficacy and safety of 2% mupirocin ointment in the treatment of primary and secondary skin infections--an open multicentre trial. Br J Clin Pract. 1989;43(8):284‐288. [PubMed 2516463]
  9. Bradley JS, Nelson JD, Barnett ED, et al, eds. Nelson's Pediatric Antimicrobial Therapy. 29th ed. American Academy of Pediatrics; 2023.
  10. Bratzler DW, Dellinger EP, Olsen KM, et al; American Society of Health-System Pharmacists; Infectious Disease Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195‐283. doi:10.2146/ajhp120568 [PubMed 23327981]
  11. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  12. Dagan R, Bar-David Y. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother. 1992;36(2):287-290. doi:10.1128/AAC.36.2.287 [PubMed 1605593]
  13. Duggal SD, Bharara T, Jena PP, et al. Staphylococcal bullous impetigo in a neonate. World J Clin Cases. 2016;4(7):191-194. doi:10.12998/wjcc.v4.i7.191 [PubMed 27458596]
  14. Gilbert M. Topical 2% mupirocin versus 2% fusidic acid ointment in the treatment of primary and secondary skin infections. J Am Acad Dermatol. 1989;20(6):1083‐1087. doi:10.1016/s0190-9622(89)70137-7 [PubMed 2502567]
  15. Goldfarb J, Crenshaw D, O'Horo J, et al. Randomized Clinical Trial of Topical Mupirocin Versus Oral Erythromycin for Impetigo. Antimicrob Agents Chemother. 1988;32(12):1780-1783. [PubMed 3149884]
  16. Hogan PG, Parrish KL, Mork RL, et al. HOME2 study: household versus personalized decolonization in households of children with methicillin-resistant Staphylococcus aureus skin and soft tissue infection-a randomized clinical trial. Clin Infect Dis. 2021;73(11):e4568-e4577. doi:10.1093/cid/ciaa752 [PubMed 32521007]
  17. Huang SS, Singh R, McKinnell JA, et al. Decolonization to reduce postdischarge infection risk among MRSA carriers. N Engl J Med. 2019;380(7):638‐650. doi:10.1056/NEJMoa1716771 [PubMed 30763195]
  18. Huang YC, Lien RI, Lin TY. Effect of mupirocin decolonization on subsequent methicillin-resistant Staphylococcus aureus infection in infants in neonatal intensive care units. Pediatr Infect Dis J. 2015;34(3):241-245. [PubMed 25742074]
  19. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  20. Khandelwal M, Bailey S, Izatt S, et al. Structural changes in silicon rubber peritoneal dialysis catheters in patients using mupirocin at the exit site. Int J Artif Organs. 2003;26(10):913‐917. doi:10.1177/039139880302601007 [PubMed 14636007]
  21. Kotloff KL, Shirley DT, Creech CB, et al. Mupirocin for Staphylococcus aureus decolonization of infants in neonatal intensive care units. Pediatrics. 2019;143(1):e20181565. doi:10.1542/peds.2018-1565 [PubMed 30587533]
  22. Kraus SJ, Eron LJ, Bottenfield GW, Drehobl MA, Bushnell WD, Cupo MA. Mupirocin cream is as effective as oral cephalexin in the treatment of secondarily infected wounds. J Fam Pract. 1998;47(6):429-433. [PubMed 9866667]
  23. Lee AS, Cooper BS, Malhotra-Kumar S, et al; MOSAR WP4 Study Group. Comparison of strategies to reduce methicillin-resistant Staphylococcus aureus rates in surgical patients: a controlled multicenter intervention trial. BMJ Open. 2013;3(9):e003126. doi:10.1136/bmjopen-2013-003126 [PubMed 24056477]
  24. Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment [published correction appears in Perit Dial Int. 2018;38(4):313]. Perit Dial Int. 2016;36(5):481‐508. doi:10.3747/pdi.2016.00078 [PubMed 27282851]
  25. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285‐292. doi:10.1093/cid/cir034 [PubMed 21217178]
  26. Livingstone V, Stringer LJ. The treatment of Staphyloccocus aureus infected sore nipples: a randomized comparative study. J Hum Lact. 1999;15(3):241-246. [PubMed 10578803]
  27. McKeown KE, Baker RB. Staphylococcal scalded skin syndrome, identification, and wound care: a case report series. Adv Neonatal Care. 2022;22(4):325-332. doi:10.1097/ANC.0000000000000979 [PubMed 35901469]
  28. Mupirocin (USP, 2%) cream [prescribing information]. Memphis, TN: Northstar RxLLC; November 2020.
  29. Mupirocin (USP, 2%) ointment [prescribing information]. Allegan, MI: Padagis; January 2022.
  30. Nelson MU, Shaw J, Gross SJ. Randomized placebo-controlled trial of topical mupirocin to reduce Staphylococcus aureus colonization in infants in the neonatal intensive care unit. J Pediatr. 2021;236:70-77. doi:10.1016/j.jpeds.2021.05.042 [PubMed 34023342]
  31. Refer to manufacturer's labeling.
  32. Savary L, De Luca A, El Arid JM, et al. Systematic skin and nasal decolonization lowers Staphylococcus infection in pediatric cardiac surgery. Arch Pediatr. 2022;29(3):177-182. doi:10.1016/j.arcped.2022.01.009 [PubMed 35094904]
  33. Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259. [PubMed 19188870]
  34. Simon A, Dresbach T, Müller A. Methicillin-resistant Staphylococcus aureus decolonization in neonates and children. Pediatr Infect Dis J. 2018;37(6):612-614. doi:10.1097/INF.0000000000001982 [PubMed 29762388]
  35. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):147-159. [PubMed 24947530]
  36. Tsai CC, Yang PS, Liu CL, Wu CJ, Hsu YC, Cheng SP. Comparison of topical mupirocin and gentamicin in the prevention of peritoneal dialysis-related infections: a systematic review and meta-analysis. Am J Surg. 2018;215(1):179‐185. doi:10.1016/j.amjsurg.2017.03.005 [PubMed 28341139]
  37. Wang MB. Etiologies of nasal obstruction: An overview. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed April 17, 2023.
  38. Weston WL, Howe W. Treatment of atopic dermatitis (eczema). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 23, 2021.
  39. White DG, Collins PO, Rowsell RB. Topical antibiotics in the treatment of superficial skin infections in general practice--a comparison of mupirocin with sodium fusidate. J Infect. 1989;18(3):221‐229. doi:10.1016/s0163-4453(89)80058-1 [PubMed 2501394]
  40. Wisgrill L, Zizka J, Unterasinger L, et al. Active surveillance cultures and targeted decolonization are associated with reduced methicillin-susceptible Staphylococcus aureus infections in VLBW infants. Neonatology. 2017;112(3):267-273. [PubMed 28704818]
Topic 9668 Version 383.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟